Document is current

Any future updates will be listed below

A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161

Crossref DOI link: https://doi.org/10.1007/s10637-022-01311-w

Published Online: 2022-10-20

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark